Evotec (EVO) Stock Price, News & Analysis

Company Overview

Evotec SE is a life sciences company headquartered in Hamburg, Germany, that provides drug discovery and development services to pharmaceutical, biotechnology and academic partners. Founded in 1993, the company supports programs from early-stage research through preclinical and clinical development, with expertise in small-molecule and biologic therapies.

Its activities include target identification and validation, screening, medicinal chemistry, pharmacology, drug manufacturing support and development services. Evotec also operates technology platforms for areas such as proteomics, data-driven drug discovery, induced pluripotent stem cells and biologics. Through its Just – Evotec Biologics business, the company develops biologic medicines and related manufacturing technologies.

Evotec serves partners internationally through research and development sites in Europe and the United States. Its collaborations span therapeutic areas including neuroscience, oncology, metabolic disease, infectious disease and immunology. The company is led by Chief Executive Officer Christian Wojczewski, who joined Evotec’s executive leadership in 2024.

Key Stats

• Today's Range: $1.36 to $1.44
• 50-Day Range: $1.53 to $2.19
• 52-Week Range: $1.36 to $4.27
• Volume: 166,947 shs
• Average Volume: 102,619 shs
• Market Capitalization: $485.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

Evotec Stock Analysis - MarketRank™

Evotec scored higher than 72% of companies evaluated by MarketBeat, and ranked 214th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Evotec has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.

Upside Potential

Evotec has a consensus price target of $3.00, representing about 119.8% upside from its current price of $1.37.

Amount of Analyst Coverage

Evotec has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Evotec are expected to grow in the coming year, from ($0.83) to $0.04 per share.

Price to Book Value per Share Ratio

Evotec has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Evotec has been sold short.

Short Interest Ratio / Days to Cover

Evotec has a short interest ratio ("days to cover") of 0.09, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evotec has recently decreased by 78.47%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evotec does not currently pay a dividend.

Dividend Growth

Evotec does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.13

News Sentiment

Evotec has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Evotec this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for EVO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Evotec to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evotec insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.00% of the stock of Evotec is held by insiders.

Percentage Held by Institutions

5.81% of the stock of Evotec is held by institutions.

Company Calendar

• Today: 10/12/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:EVO
• CIK: 1412558
• Web: www.evotec.com
• Phone: 49-40-560-81-0
• Fax: 49-40-5608-1222
• Employees: 4,553
• Year Founded: 1993

Price Target and Rating

• Average Price Target for Evotec: $3.00
• High Price Target: $4.00
• Low Price Target: $2.00
• Potential Upside/Downside: +119.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$117.12 million
• Net Margins: -26.20%
• Pretax Margin: -24.26%
• Return on Equity: -24.93%
• Return on Assets: -11.35%

Debt

• Debt-to-Equity Ratio: 0.62
• Current Ratio: 2.33
• Quick Ratio: 2.21

Sales & Book Value

• Annual Sales: $717.28 million
• Price / Sales: 0.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.59 per share
• Price / Book: 0.53

Miscellaneous

• Outstanding Shares: 355,819,000
• Free Float: N/A
• Market Cap: $485.69 million
• Optionable: Not Optionable
• Beta: 1.97